peter kolchinsky age

Prior to MP, she was a Consultant at Clarion Healthcare. His most recent role at Biogen was as Senior Vice President, U.S. Commercial, where he was the general manager of the MS, hemophilia, and SMA franchises. Peter Kolchinsky Net Worth | Age, Height, Weight, Dating And More In this role he works closely with RAs Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. Previously, Derek covered solid tumor oncology landscapes. Gunes holds a BSc in Biological Sciences and Bioengineering from Sabanci University, a MSc in Molecular and Cellular Biology and a PhD in Biochemistry from the University of Heidelberg. He is co-founder and CEO of Clear Creek Bio, an RA Capital portfolio company. Prior to RA, Rob spent 21 years at the Broad Institute of MIT and Harvard, most recently as the Senior Director of Technology Development and a Principal Investigator. Candice previously worked as the Director of Executive Office and Administration at Flywire. Brian's primary responsibility at RA Capital is to manage the firm's IT Operations needs. Vanderpump Rules' Peter Madrigal's Age. Her primary responsibility is leading and executing full cycle recruiting across all newcos and portfolio companies. Josh holds a BS in Genetics, Genomics, and Biotechnology with a Minor in Business from Brigham Young University. He holds additional board appointments with several well-respected nonprofit organizations, including the Institute for Clinical and Economic Review (ICER), the Personalized Medicine Coalition, the Harvard Business School Healthcare Initiative, NEHI (Network for Excellence in Health Innovation), and the Massachusetts Rare Disease Advisory Council. Kat has a BS in Business Administration, majoring in Accounting from the University of Minnesota, Carlson School of Management. Alex has a BA with a triple-major in Finance, Economics, and Math from UMass Lowell. Peter Kolchinsky | RA Capital Management Profile - TipRanks.com (L-R) Robert Morgan, Jamie Anderson and Mark Blutman, collaborators on forthcoming 'Arigato Tokyo' Courtesy/Getty. She received a B.Sc. Prior to his time at Merck, Michael held discovery leadership roles at Immunext and Tolerx. He previously held roles as VP Product Manager - Data Services at Charles River Development (a State Street Company) and Senior Business Analyst in Capital Markets at Bain Capital Credit and State Street Global Exchange, DataGX. Cony received a BSc in Applied Biology from the University of London and an MBA from The Open University, Milton Keynes UK. He earned his PhD in Biomedical Science & Translational Medicine from Cedars-Sinai Medical Center and completed his Postdoctoral Fellowship in Molecular Pathology & Oncology at Harvard Medical School. Peter Pan & Wendy supports the theory that Peter Pan is the real villain of his respective franchise with its depiction of the beloved Disney character. Sophie was a principal investigator in the Early Phase Trials Team at GSTT and has extensive experience in the delivery of early to late phase oncology trials. Matts primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Toms primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Prior to joining RA, Jesse was Senior Director of Discovery at Kymera Therapeutics. Prior to joining RAVen, Maryann was Director of Business Operations and HR at Q32 Bio where she wore many hats helping to establish the companys business infrastructure including IT, contract management, facilities, administrative support, Human Resources, recruiting, internal communications and was a strong driver of company culture. Joel received his doctorate in Organic Chemistry from Columbia University and his bachelors in Chemistry from the University of Pennsylvania. Tom has a BS in Physiological Sciences from University of California Los Angeles. Dans primary responsibility at RA Capital is to identify compelling opportunities to help facilitate new company creation or investments in emerging seed-stage companies. Shan Shan Wang is an Associate Director within the TechAtlas division at RA Capital Management. He was a faculty member at the University of Rochester School of Medicine prior to joining Merck Research Laboratories in 2004. Candice has a BS in Mass Communications from Emerson College. Alonso Ricardo is an Entrepreneur in Residence at RA Capital, where he works closely with RAs Venture Team to evaluate drug discovery platforms and initiate novel therapeutics programs. Prior to Baupost, he spent over five years as a Controller at Centerbridge Partners, LP, where he was responsible for accounting and valuation for the credit fund business, as well as the management company (US and Europe) and associated functions. RA Capital and CEO of Arcuate Therapeutics. Her doctoral research focused on bacteriophage-mediated regulation of bacterial transcription. Astha holds a BA in Biochemistry and Molecular Biology (with a minor in Physics) from Clark University. As Executive Director of Business Development at Celgene, Emily was responsible for all aspects of deal evaluation, negotiation, and execution for licensing deals, mergers and acquisitions, and collaborations, with a focus on immune-inflammatory and neurodegenerative diseases. Max has a BS in Biology from the State University of New York at Fredonia and a PhD in Cellular and Molecular Biology from the University of Michigan. Her graduate research investigated synaptic translation in syndromic autism. Prithviraj Singha Roy is a Senior Associate on the Investment Team at RA Capital Management. Emily Gransky is VP of Recruiting at RA Ventures (RAVen). Tweet With huge thanks to RA Capital's Alex Martinez-Forte and Jacqueline Rhuda for extensive data analysis. Michael received his undergraduate degree at Georgetown University and his medical degree at the Medical University of South Carolina. Her graduate research investigated novel small molecule approaches to treating vestibular schwannoma and neurofibromatosis type 2. BioVentures. Prior to joining biotech/pharma, she was a specialist in the corporate finance team at McKinsey & Co, focused on corporate transactions. Nadim has 11+ years experience in commercializing drug discovery across diverse indications and modalities. Peter is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools and serves on the boards of publicly- and privately-held life science companies. He worked previously at Global Prior Art, an intellectual property analysis firm, as a Partner and the Director of the Life Sciences Division. Soumya has contributed to over 75 drug discovery programs ranging from small startups to large pharma, leading to nine development candidates currently in various stages of clinical trials. Brett holds a BS from Washington University, St. Louis and a JD from Duquesne University School of Law and is admitted to practice law in PA. Brett previously served as a Clerk for the Washington County Court of Common Pleas in PA. Emilie Schleer is the Senior Investor Relations Manager with the Operations Team at RA Capital Management. Timothy Noyes is an Advisor for RA Capital Management. Brigid holds a BS in Chemistry (Hons) from the Commonwealth Honors College at the University of Massachusetts, Amherst (2002) and a PhD in Materials Science and Engineering from Johns Hopkins University (2009). Jake Simson is a Partner at RA Capital Management. In addition to The Great American Drug Deal, he is the author of The Entrepreneurs Guide to a Biotech Startup. He is the co-founder and Chairman of the Board of Directors of Spero Therapeutics, and past President, CEO and member of the Board of Directors of Achillion Pharmaceuticals. Eric holds a MAcc from Bentley University and a BS in Finance from George Mason University. Chris Caliri is the Chief Information Officer at RA Capital Management. Josh is currently a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital. Prior to that, David worked as Director of Operations for Wingspan Investment Management, LP and held operations positions at Brencourt Advisors and Silver Point Capital, LP. Peter Kolchinsky 285 Followers Scientist turned biotech investor, always learning, guided by fatherhood, share The Economist's world view, inspired to write by Hamilton's Federalist Papers. Nadim Shohdy is an EIR at RA Capital. Kathryn Spencer is an Executive Assistant at RA Capital Management. Prior to Flywire, she worked as an Executive/Personal Assistant at Spark Capital. Brian Lewandowski is an Analyst on the Investment Team at RA Capital Management. Daniel has a BS in Mechanical Engineering from Lehigh University and a MS in Energy Policy & Climate from Johns Hopkins University. Her graduate research investigated novel epigenetic regulators in glioblastoma. Jake works on both public and private investments and serves as a Board Director for Xenikos, B.V, Tyra Biosciences, AavantiBio, and DiCE Molecules. Derek works on both public and private investments and serves as a Board Director for 89Bio, Achilles Therapeutics, iTeos Therapeutics, Connect Bio, CANbridge, andWerewolf Therapeutics. Tylers primary responsibility at RA Capital isdesigning and maintaining the RA Capital website and assisting in the creation and design of interactive platforms at RA Capital and it's portfolio companies founded through the firm's incubator, RA Ventures. Christys primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. He holds Microsoft 365 and Microsoft certifications as Messaging Administrator Associate, Teams Administrator Associate, Teamwork Administrator Associate, and Azure Administrator Associate. Prior to joining RA Capital, Emilie was a Vice President of Investor Relations at THL Credit.

Steve Weiss Mutesix Net Worth, Articles P